A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of HRS-7085 Tablets in Healthy Subjects, With Assessment of Food Effects

Phase 1 Unknown 70 enrolled Shandong Suncadia Medicine Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-parallel-controlled, Phase I clinical trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of HRS-7085 tablets in healthy subjects, with assessment of food effects

Timeline

Start: 2023-12
Primary completion: 2024-06
Completion: 2024-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-7085	Unknown	2 mg	Oral
Subject	HRS-7085	Unknown	5 mg	Oral
Subject	HRS-7085	Unknown	8 mg	Oral
Subject	HRS-7085	Unknown	10 mg	Oral
Subject	HRS-7085	Unknown	12 mg	Oral
Subject	HRS-7085	Unknown	15 mg	Oral

A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of HRS-7085 Tablets in Healthy Subjects, With Assessment of Food Effects

Summary

Timeline

Drugs

Indications